Cancer immunogenomics is an emerging field that bridges genomics and immunology. The
establishment of large-scale genomic collaborative efforts along with the development of …

The field of cancer neoantigen investigation has developed swiftly in the past decade.
Predicting novel and true neoantigens derived from large multi-omics data became difficult …

Alternative splicing (AS) is prevalent in cancer, generating an extensive but largely
unexplored repertoire of novel immunotherapy targets. We describe I soform peptides from …

Immunotherapy has emerged as a crucial strategy to combat cancer by “reprogramming” a
patient's own immune system. Although immunotherapy is typically reserved for patients with …

Background Neoantigens are critical for anti-tumor immunity and have been long-
envisioned as promising therapeutic targets. However, current neoantigen analyses mostly …

Motivation Elimination of cancer cells by T cells is a critical mechanism of anti-tumor
immunity and cancer immunotherapy response. T cells recognize cancer cells by …

While immunotherapy is typically reserved for cancer patients with a high mutational burden,
neoantigens produced from post-transcriptional regulation provide a possible untapped …

Background Cancer neoantigens arise from protein-altering somatic mutations in tumor and
rank among the most promising next-generation immuno-oncology agents when used in …

Intronic polyadenylation (IPA) refers to a particular type of alternative polyadenylation where
a gene makes use of a polyadenylation site located within its introns. Aberrant IPA events …

Immunoproteasome-reprogrammed mesenchymal stromal cells (IRMs) can surpass
dendritic cells at eliciting tumor-specific immunity. However, the current IRM vaccination …